Biotech
Bambusa Therapeutics
Bambusa Therapeutics raises $90M Series A at $400M valuation
$90M
Total Raised
Series A
Latest Round
2022
Founded
60+
Employees
San Francisco, CA
1 min read
Quick Facts
Valuation
$400M
Latest Round Size
$90M
Latest Round Date
February 2025
Bambusa Therapeutics: Series A Funding Round
Bambusa Therapeutics has successfully raised $90M in Series A funding, reaching a valuation of $400M.
Company Overview
Bispecific antibodies for immunology
Funding Details
The Series A round was led by Arch Venture Partners, with participation from Foresite Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
Bambusa Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series A
- Foresite Capital: Verified investor in Series A
Key Investors
Arch Venture Partners
Lead Investor
Verified investor in Series A
Foresite Capital
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M